Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2001

View Archived Issues

Calcium-like peptides as leads in the development of antiallergic agents

ImClone Systems and Bristol-Myers Squibb reach agreement to develop anticancer drug IMC-C225

Amgen and Praecis end their Plenaxis agreement

ABCA1 gene as a new drug target in cardiovascular disease

Phase II trial data support efficacy of duloxetine in stress urinary incontinence

NeuGene antisense drug targeting drug-metabolizing liver enzyme enters human testing

Mirostipen advances in clinical trials for preventing severe side effects of chemotherapy

IND filing expected soon for Myriad anti-HIV compound based on positive preclinical data

Name change for Checkpoint Genetics

BIIR-561-CL: effects in animal models of neuronal overexcitation

Nonpeptide N/OFQ receptor agonist shows promise for the treatment of anxiety

Rodent pharmacokinetic and efficacy studies support use of ABT-773 in respiratory infections

New strength of Zomig-ZMT approved by FDA

Molecular Diagnostics to commence clinical trial of cancer diagnostic test with BCCA

Human Genome Sciences receives FDA approval to begin clinical trials of BLyS

Corvas and Dyax collaborate to discover cancer therapeutics

Significant results obtained for CRL-5861 in animal model of spinal cord injury

Genasense granted fast track designation for multiple myeloma

Multiple Guidant programs for drug-coated stents in progress

Hybrigen and Bionomics announce alliance to develop gene-based products

Indian research institute evaluates andrographolide derivatives

DNA-targeted anticancer agents under study at Mitsui Chemicals

Novo Nordisk patents new series of GSK-3 inhibitors

Abbott's new p38 MAP kinase inhibitors useful in inflammation

Agents with affinity for human 5-HT7 receptor claimed by AHP for CNS disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...